About this item:

443 Views | 765 Downloads

Author Notes:

Correspondence: yuetsu@s4.dion.ne.jp

YTan conceived of the study, participated in its design and coordination, carried out the FCM assays, and drafted the manuscript.

MM and MN carried out molecular studies, YTak established the CD83-expressing cell line and ATL T cell lines, HF carried out the cell sorting, RT produced, purified, and labeled mAbs, confirmed their specificities, and made in-house EILSA kits, TF and TT collected blood samples from HTLV-I+ patients, and AAA participated in the design of the study and helped to draft the manuscript.

All authors read and approved the final manuscript.

We thank Prof. M. Fujii at Niigata University for providing Ton1 cells.

The authors declare that they have no competing interests.

Subjects:

Research Funding:

This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare of Japan, and Okinawa prefecture.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Virology
  • CD83
  • HTLV
  • Tax
  • ATL
  • PGE2
  • NF-KAPPA-B
  • ACTIVATED DENDRITIC CELLS
  • SOLUBLE CD83
  • TRANSCRIPTIONAL ACTIVATOR
  • PERIPHERAL-BLOOD
  • IMMUNE-RESPONSES
  • HUMAN RETROVIRUS
  • HUMAN-SERA
  • LYMPHOCYTES
  • ANTIBODIES

Human T-cell leukemia virus type-I Tax induces the expression of CD83 on T cells

Tools:

Journal Title:

Retrovirology

Volume:

Volume 12, Number 56

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: CD83, a cell surface glycoprotein that is stably expressed on mature dendritic cells, can be transiently induced on other hematopoietic cell lineages upon cell activation. In contrast to the membrane form of CD83, soluble CD83 appears to be immunosuppressive. In an analysis of the phenotype of leukemic CD4+ T cells from patients with adult T-cell leukemia (ATL), we found that a number of primary CD4+ T cells became positive for cell surface CD83 after short-term culture, and that most of these CD83+ CD4+ T cells were positive for human T-cell leukemia virus type-I (HTLV-I) Tax (Tax1). We hypothesized that Tax1 is involved in the induction of CD83. Result: We found that CD83 was expressed selectively on Tax1-expressing human CD4+ T cells in short-term cultured peripheral blood mononuclear cells (PBMCs) isolated from HTLV-I+ donors, including ATL patients and HTLV-I carriers. HTLV-I-infected T cell lines expressing Tax1 also expressed cell surface CD83 and released soluble CD83. CD83 can be expressed in the JPX-9 cell line by cadmium-mediated Tax1 induction and in Jurkat cells or PBMCs by Tax1 introduction via infection with a recombinant adenovirus carrying the Tax1 gene. The CD83 promoter was activated by Tax1 in an NF-κB-dependent manner. Based on a previous report showing soluble CD83-mediated prostaglandin E2 (PGE2) production from human monocytes in vitro, we tested if PGE2 affected HTLV-I propagation, and found that PGE2 strongly stimulated expression of Tax1 and viral structural molecules. Conclusions: Our results suggest that HTLV-I induces CD83 expression on T cells via Tax1 -mediated NF-κB activation, which may promote HTLV-I infection in vivo.

Copyright information:

© 2015 Tanaka et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote